2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targetsTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeksAssociation between specific types of parent stressors and fast-food consumption among parents and children
Bautista T, Fogelman N, Lartigue S, Silverman W, Jastreboff A, Sinha R. Association between specific types of parent stressors and fast-food consumption among parents and children. Eating Behaviors 2023, 49: 101724. PMID: 37054487, PMCID: PMC10247538, DOI: 10.1016/j.eatbeh.2023.101724.Peer-Reviewed Original ResearchConceptsHousehold chaosParent stressorsYoung childrenOnly significant predictorSignificant predictorsFast food consumptionStress interventionsSeparate regression modelsParentsSpecific typesYear oldsChildrenStressorsFast food intakeChildren's fast food consumptionPredictorsFinal modelHealthy foodsOldsBehaviorStressInterventionTurnBody mass indexFindings
2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planObstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. American Journal Of Kidney Diseases 2022, 80: 783-793. PMID: 36280397, DOI: 10.1053/j.ajkd.2022.06.007.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsManagement of obesityLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2021
Impact of Obesity on Heart Transplantation Outcomes
Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10: e021346. PMID: 34854316, PMCID: PMC9075353, DOI: 10.1161/jaha.121.021346.Peer-Reviewed Original ResearchConceptsBody mass indexHigher BMI categoriesImpact of obesityHeart transplantation outcomesBMI categoriesTransplantation outcomesHeart transplantationHigher body mass indexAllocation system changeAdvanced heart failureOrgan Sharing databaseObese BMI categoriesVentricular assist deviceNew Organ ProcurementPosttransplant deathPosttransplantation deathPosttransplant mortalityBackground PatientsBMI 18.5Adult patientsCohort studyHeart failureHeart transplantSharing databaseWaitlist deathsCOVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society
Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity 2021, 29: 1575-1579. PMID: 34212511, PMCID: PMC8441899, DOI: 10.1002/oby.23251.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineObesity SocietyCOVID-19-associated hospitalizationPosition statementEfficacy of vaccinesSARS-CoV-2Pfizer-BioNTechAvailable vaccinesUS FoodDrug AdministrationObesityVaccineEmergency useHigh efficacyPeer-reviewed literatureScientific evidenceCOVID-19EfficacyTime of publicationBriefing documentsDefinitive wayHospitalizationPatientsVaccinationAdministrationTesting the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder
Angarita GA, Matuskey D, Pittman B, Costeines JL, Potenza MN, Jastreboff AM, Schmidt HD, Malison RT. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug And Alcohol Dependence 2021, 221: 108614. PMID: 33621809, PMCID: PMC8026565, DOI: 10.1016/j.drugalcdep.2021.108614.Peer-Reviewed Original ResearchConceptsCocaine use disorderGLP-1Use disordersGLP-1 receptor agonist exenatideGlucagon-like peptide-1 analogSubjective effectsEfficacy of exenatideLevels of amylinPreclinical rodent studiesPeptide-1 analogVisual analog scaleGLP-1 analoguesSelf-reported euphoriaInfusion of cocaineSelf-administer cocaineAcute pretreatmentSecondary outcomesPrimary outcomeAnalog scaleHormone levelsRodent studiesExenatidePlaceboCocaine infusionsCUD subjects
2020
Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study
Bini J, Bhatt S, Hillmer AT, Gallezot JD, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging And Biology 2020, 22: 1124-1131. PMID: 32133575, PMCID: PMC7351613, DOI: 10.1007/s11307-020-01490-z.Peer-Reviewed Original ResearchConceptsBody mass indexPositron emission tomographyDehydrogenase type 1Mass indexObese individualsEnzyme 11β-hydroxysteroid dehydrogenase type 1Whole brainType 1Higher body mass indexPositron emission tomography studyVT valuesSevere Alzheimer's diseaseEmission tomography studiesSteroid stress hormonesAge-associated increaseMean whole brainSignificant age-associated increaseRegional distribution volumesVisceral adiposityInsulin resistanceActive cortisolExcess cortisolInactive cortisoneMemory dysfunctionParietal lobe
2019
Commentary from the American Association of Clinical Endocrinologists on the U.S. Preventive Services Task Force Recommandations Regarding Weight Loss Interventions
Garvey WT, Jastreboff AM. Commentary from the American Association of Clinical Endocrinologists on the U.S. Preventive Services Task Force Recommandations Regarding Weight Loss Interventions. Endocrine Practice 2019, 25: 394-395. PMID: 31013160, DOI: 10.4158/ep-2018-0597.Commentaries, Editorials and Letters
2018
Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study
Jastreboff AM, Chaplin TM, Finnie S, Savoye M, Stults-Kolehmainen M, Silverman WK, Sinha R. Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study. The Journal Of Pediatrics 2018, 202: 136-142.e1. PMID: 30241766, PMCID: PMC6203652, DOI: 10.1016/j.jpeds.2018.07.011.Peer-Reviewed Original ResearchConceptsChildhood obesityChild body mass indexGroup interventionPhysical activity counselingRandomized pilot studyBody mass indexChildhood obesity riskControl group interventionEarly childhood obesityStress interventionsActivity counselingMass indexObesity riskPhysical activityTherapeutic mechanismObesityGroup attendanceRisk 2Pilot studyInterventionSignificant increaseLow-income parentsGreater improvementRiskParent-child dyads
2017
Stress, cortisol, and other appetite‐related hormones: Prospective prediction of 6‐month changes in food cravings and weight
Chao AM, Jastreboff AM, White MA, Grilo CM, Sinha R. Stress, cortisol, and other appetite‐related hormones: Prospective prediction of 6‐month changes in food cravings and weight. Obesity 2017, 25: 713-720. PMID: 28349668, PMCID: PMC5373497, DOI: 10.1002/oby.21790.Peer-Reviewed Original ResearchConceptsFuture weight gainAppetite-related hormonesFood cravingsChronic stressWeight gainProspective community cohortFood Craving InventoryTotal ghrelinCommunity cohortBlood drawMorning cortisolClinical covariatesHormone levelsBody weightCortisol responseHigher food cravingsHigher cortisolCortisolCumulative Adversity InterviewCravingLinear mixed modelsBaselineGhrelinHormoneMonths
2016
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology 2016, 41: 3042-3050. PMID: 27374277, PMCID: PMC5101552, DOI: 10.1038/npp.2016.115.Peer-Reviewed Original ResearchConceptsBody mass indexVentral striatumObese individualsD2/3R availabilityOB individualsReward regionsSubstantia nigra/ventral tegmental areaDopamine D2/3 receptor availabilityNormal-weight individualsTreatment of obesityVentral tegmental areaNovel pharmacologic targetsD2/3 receptor availabilitySN/VTAAgonist tracersOverweight cohortMass indexWeight individualsTegmental areaBrain reward regionsAntagonist tracersPharmacologic targetReceptor availabilitySecondary analysisNW individualsUtility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers
Quinn SM, Ambrosino JM, Doyle EA, Weyman K, Tamborlane WV, Jastreboff AM. Utility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers. Endocrine Practice 2016, 22: 1104-1110. PMID: 27295017, DOI: 10.4158/ep151190.or.Peer-Reviewed Original ResearchConceptsChart reviewEating Problem SurveyDiabetes distressAdditional patientsYoung adultsDepressive symptomsProblem SurveyPoor glycemic controlDiabetes Eating Problem SurveyBody mass indexDiabetes Distress ScalePatient Health QuestionnaireType 1 diabetesTransition clinicGlycemic controlMass indexPHQ-8Formal screeningAdult providersGlycated hemoglobinSymptomatic depressionAdult careHealth QuestionnaireMetabolic controlPatientsFunctional Connectivity During Exposure to Favorite-Food, Stress, and Neutral-Relaxing Imagery Differs Between Smokers and Nonsmokers
Garrison KA, Sinha R, Lacadie CM, Scheinost D, Jastreboff AM, Constable RT, Potenza MN. Functional Connectivity During Exposure to Favorite-Food, Stress, and Neutral-Relaxing Imagery Differs Between Smokers and Nonsmokers. Nicotine & Tobacco Research 2016, 18: 1820-1829. PMID: 26995796, PMCID: PMC4978981, DOI: 10.1093/ntr/ntw088.Peer-Reviewed Original ResearchConceptsFunctional connectivityBrain regionsSupramarginal gyrusFavorite-food cuesSmoking-related alterationsMagnetic resonance imaging studyBrain functional connectivity patternsPrevious functional magnetic resonance imaging (fMRI) studiesTobacco use disorderBrain networksIntrinsic connectivity distributionResonance imaging studyFunctional magnetic resonance imaging studyFunctional connectivity patternsMultiple brain networksSmoking cessationNonsmokersPosterior insulaRolandic operculumSmokersFunctional brain networksImaging studiesGreater connectivityNeural responsesRecent reports
2014
Blunted striatal responses to favorite-food cues in smokers
Jastreboff AM, Sinha R, Lacadie CM, Balodis IM, Sherwin R, Potenza MN. Blunted striatal responses to favorite-food cues in smokers. Drug And Alcohol Dependence 2014, 146: 103-106. PMID: 25444233, PMCID: PMC4272899, DOI: 10.1016/j.drugalcdep.2014.09.006.Peer-Reviewed Original ResearchConceptsFavorite-food cuesNeural responsesNeutral-relaxing conditionsBody mass indexCue exposureBrain mechanismsRewarding stimuliBrain responsesStriatal responsesCuesDiminished activationLower body mass indexLean body massSmoking cessationMass indexSmoking statusFMRIInsulaSmokersWeight gainStimuliRatingsAudiotapesCaudateBody massSex differences in the association between dietary restraint, insulin resistance and obesity
Jastreboff AM, Gaiser EC, Gu P, Sinha R. Sex differences in the association between dietary restraint, insulin resistance and obesity. Eating Behaviors 2014, 15: 286-290. PMID: 24854820, PMCID: PMC4032476, DOI: 10.1016/j.eatbeh.2014.03.008.Peer-Reviewed Original ResearchConceptsBody mass indexInsulin resistanceMass indexRestrained eatingHomeostatic model assessmentSex differencesObese weight categoriesEating Behavior QuestionnaireEventual weight gainDutch Eating Behavior QuestionnaireHOMA-IRPlasma insulinObservational studyModel assessmentAbstractTextWeight categoriesWeight gainDietary restraintLarge community sampleFood consumptionWomenMenAIMSCommunity sampleBehavior Questionnaire
2013
Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children
Hairston KG, Ducharme JL, Treuth MS, Hsueh WC, Jastreboff AM, Ryan KA, Shi X, Mitchell BD, Shuldiner AR, Snitker S. Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children. Diabetes Care 2013, 36: 873-878. PMID: 23093661, PMCID: PMC3609522, DOI: 10.2337/dc12-0934.Peer-Reviewed Original ResearchConceptsMin/dayPhysical activityOld Order AmishNutrition Examination Survey dataBMI z-scoreVigorous physical activityComparison of BMIHip-worn accelerometersOld Order Amish childrenNon-Hispanic white populationPediatric overweightMean BMIExcess weightNational HealthLong-term protectionLow prevalenceES groupNHANES estimatesChildhood factorsZ-scorePA levelsBMIDiabetesAnthropometric dataWhite population